The therapeutic value of adding belimumab to the standard treatment in the treatment of adult patients with active, autoantibody-positive SLE with a high degree of disease activity is comparable with that of “usual treatment of choice”.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.